Three Dimensional Ultrasonographic Detection of Human Ovulation
Three Dimensional Ultrasonographic Detection of Human Ovulation and Anovulation
University of Saskatchewan
30 participants
Apr 22, 2024
INTERVENTIONAL
Conditions
Summary
The research aims to compare diagnosis of ovulation and anovulation in 2D and 3D ultrasonography.
Eligibility
Inclusion Criteria2
- Healthy biological females
- Regular menstrual cycles (21-35 days)
Exclusion Criteria17
- BMI \<18 or \>30
- Pregnancy
- Breastfeeding mothers
- History of infertility
- History of hysterectomy or oophorectomy
- Reproductive health issues that can interfere with study outcomes
- Smoking
- Not on any hormonal medication that affects reproduction (including hormonal contraception)
- History of metabolic syndrome or untreated thyroid disease
- Contra-indication to non-steroidal anti-inflammatory drug (NSAID) use. These include:
- Gastric ulcers or gastro-intestinal bleeding
- History of myocardial infarction or a coronary artery bypass
- Cerebrovascular disease
- Hypertension
- Chronic or acute renal failure
- Severe liver disease
- Nasal polyp syndrome
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
Early morning urine tests to assay reproductive hormones
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06433453